Myocardial hypertrophic preconditioning attenuates cardiomyocyte hypertrophy and slows progression to heart failure through upregulation of S100A8/A9

Circulation

Volumn 131, Issue 17, 2015, Pages 1506-1517

  Wei, Xuan ^a   Wu, Bing ^a   Zhao, Jing ^a   Zeng, Zhi ^a   Xuan, Wanling ^a   Cao, Shiping ^a   Huang, Xiaobo ^a   Asakura, Masanori ^b   Xu, Dingli ^a   Bin, Jianping ^a   Kitakaze, Masafumi ^b   Liao, Yulin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Cardiomegaly; Heart failure; Myocardial preconditioning; S100A8 protein; S100A9 protein

Indexed keywords

CALCIUM BINDING PROTEIN; CALGRANULIN A; MESSENGER RNA; NORADRENALIN; PHENYLEPHRINE; PROTEIN S 100A9; UNCLASSIFIED DRUG; CALCINEURIN; CALGRANULIN B; HYBRID PROTEIN; S100A9 PROTEIN, MOUSE; TRANSCRIPTION FACTOR NF-AT C3; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CARDIOVASCULAR PARAMETERS; CELL STIMULATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; GENE SILENCING; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; ISCHEMIC PRECONDITIONING; LUNG WEIGHT BODY WEIGHT RATIO; MALE; MOUSE; MYOCARDIAL HYPERTROPHIC PRECONDITIONING; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRANSVERSE AORTIC CONSTRICTION; UPREGULATION; ANIMAL; AORTA VALVE STENOSIS; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; COMPLICATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; AORTIC VALVE STENOSIS; CALCINEURIN; CALGRANULIN A; CALGRANULIN B; CARDIOMYOPATHY, HYPERTROPHIC; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; GENETIC VECTORS; HEART FAILURE; HYPERTROPHY; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; PHENYLEPHRINE; RATS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER;

EID: 84929377954     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.013789     Document Type: Article

References (56)

1. Meerson FZ. Compensatory hyperfunction of the heart and cardiac insufficiency. Circ Res. 1962;10:250-258.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566. doi: 10.1056/NEJM199005313222203.
3. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358:1370-1380. doi: 10.1056/NEJMra072139.
4. Bjørnstad JL, Sjaastad I, Nygård S, Hasic A, Ahmed MS, Attramadal H, Finsen AV, Christensen G, Tønnessen T. Collagen isoform shift during the early phase of reverse left ventricular remodelling after relief of pressure overload. Eur Heart J. 2011;32:236-245. doi: 10.1093/eurheartj/ehq166.
5. Lund O, Emmertsen K, Dørup I, Jensen FT, Flø C. Regression of left ventricular hypertrophy during 10 years after valve replacement for aortic stenosis is related to the preoperative risk profile. Eur Heart J. 2003;24:1437-1446.
6. Chen J, Chemaly ER, Liang LF, LaRocca TJ, Yaniz-Galende E, Hajjar RJ. A new model of congestive heart failure in rats. Am J Physiol Heart Circ Physiol. 2011;301:H994-1003. doi: 10.1152/ajpheart.00245.2011.
7. Yang DK, Choi BY, Lee YH, Kim YG, Cho MC, Hong SE, Kim do H, Hajjar RJ, Park WJ. Gene profiling during regression of pressure overload-induced cardiac hypertrophy. Physiol Genomics. 2007;30:1-7. doi: 10.1152/physiolgenomics.00246.2006.
8. Miana LA, Assad RS, Abduch MC, Gomes GS, Nogueira AR, Oliveira FS, Telles BL, Souto MT, Silva GJ, Stolf NA. Intermittent systolic overload promotes better myocardial performance in adult animals. Arq Bras Cardiol. 2010;95:364-372.
9. Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006;116:1547-1560. doi: 10.1172/JCI25397.
10. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136.
11. Shizukuda Y, Mallet RT, Lee SC, Downey HF. Hypoxic preconditioning of ischaemic canine myocardium. Cardiovasc Res. 1992;26:534-542.
12. Kim CH, Choi H, Chun YS, Kim GT, Park JW, Kim MS. Hyperbaric oxygenation pretreatment induces catalase and reduces infarct size in ischemic rat myocardium. Pflugers Arch. 2001;442:519-525.
13. Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 1995;27:883-892.
14. Gourine AV, Molosh AI, Poputnikov D, Bulhak A, Sjöquist PO, Pernow J. Endothelin-1 exerts a preconditioning-like cardioprotective effect against ischaemia/reperfusion injury via the ET(A) receptor and the mitochondrial K(ATP) channel in the rat in vivo. Br J Pharmacol. 2005;144:331-337. doi: 10.1038/sj.bjp.0706050.
15. Elliott GT. Monophosphoryl lipid A: a novel agent for inducing pharmacologic myocardial preconditioning. J Thromb Thrombolysis. 1996;3:225-237.
16. Baumann M, Sollinger D, Roos M, Lutz J, Heemann U. Prehypertensive preconditioning improves adult antihypertensive and cardioprotective treatment. J Pharmacol Exp Ther. 2010;332:1121-1126. doi: 10.1124/jpet.109.161075.
17. Stansfield WE, Charles PC, Tang RH, Rojas M, Bhati R, Moss NC, Patterson C, Selzman CH. Regression of pressure-induced left ventricular hypertrophy is characterized by a distinct gene expression profile. J Thorac Cardiovasc Surg. 2009;137:232-8, 238e1. doi: 10.1016/j.jtcvs.2008.08.019.
18. Cuspidi C, Sala C, Negri F, Mancia G, Morganti A; Italian Society of Hypertension. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012;26:343-349. doi: 10.1038/jhh.2011.104.
19. Cacciapuoti F. Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives. J Am Soc Hypertens. 2011;5:449-455. doi: 10.1016/j.jash.2011.08.006.
20. Korhonen T, Hänninen SL, Tavi P. Model of excitation-contraction coupling of rat neonatal ventricular myocytes. Biophys J. 2009;96:1189-1209. doi: 10.1016/j.bpj.2008.10.026.
21. Tiede K, Melchior-Becker A, Fischer JW. Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblasts. Basic Res Cardiol. 2010;105:99-108. doi: 10.1007/s00395-009-0049-8.
22. Liao Y, Ishikura F, Beppu S, Asakura M, Takashima S, Asanuma H, Sanada S, Kim J, Ogita H, Kuzuya T, Node K, Kitakaze M, Hori M. Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. Am J Physiol Heart Circ Physiol. 2002;282:H1703-H1708. doi: 10.1152/ajpheart.00238.2001.
23. Liao Y, Bin J, Asakura M, Xuan W, Chen B, Huang Q, Xu D, Ledent C, Takashima S, Kitakaze M. Deficiency of type 1 cannabinoid receptors worsens acute heart failure induced by pressure overload in mice. Eur Heart J. 2012;33:3124-3133. doi: 10.1093/eurheartj/ehr246.
24. Mavroudis C, Backer CL. Arterial switch after failed atrial baffle procedures for transposition of the great arteries. Ann Thorac Surg. 2000;69:851-857.
25. Poirier NC, Mee RB. Left ventricular reconditioning and anatomical correction for systemic right ventricular dysfunction. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2000;3:198-215.
26. Sekarski N, Hurni M, von Segesser LK, Meijboom EJ, Di Bernardo S. Adaptable pulmonary artery band for late arterial switch procedure in transposition of the great arteries. Ann Thorac Surg. 2012;94:1311-1316. doi: 10.1016/j.athoracsur.2012.04.095.
27. Bishop SP, Melsen LR. Myocardial necrosis, fibrosis, and DNA synthesis in experimental cardiac hypertrophy induced by sudden pressure overload. Circ Res. 1976;39:238-245.
28. Christakis GT, Joyner CD, Morgan CD, Fremes SE, Buth KJ, Sever JY, Rao V, Panagiotopoulos KP, Murphy PM, Goldman BS. Left ventricular mass regression early after aortic valve replacement. Ann Thorac Surg. 1996;62:1084-1089. doi: 10.1016/0003-4975(96)00533-4.
29. Walther T, Falk V, Langebartels G, Kruger M, Bernhardt U, Diegeler A, Gummert J, Autschbach R, Mohr FW. Prospectively randomized evaluation of stentless versus conventional biological aortic valves: Impact on early regression of left ventricular hypertrophy. Circulation. 1999;100:II6-10.
30. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97:2316-2322.
31. Müller J, Wallukat G, Weng YG, Dandel M, Spiegelsberger S, Semrau S, Brandes K, Theodoridis V, Loebe M, Meyer R, Hetzer R. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation. 1997;96:542-549.
32. Rodrigue-Way A, Burkhoff D, Geesaman BJ, Golden S, Xu J, Pollman MJ, Donoghue M, Jeyaseelan R, Houser S, Breitbart RE, Marks A, Acton S. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. J Heart Lung Transplant. 2005;24:73-80. doi: 10.1016/j.healun.2003.10.016.
33. Perera C, McNeil HP, Geczy CL. S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol. 2010;88:41-49. doi: 10.1038/icb.2009.88.
34. Lim SY, Raftery MJ, Geczy CL. Oxidative modifications of DAMPs suppress inflammation: the case for S100A8 and S100A9. Antioxid Redox Signal. 2011;15:2235-2248. doi: 10.1089/ars.2010.3641.
35. Goyette J, Geczy CL. Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids. 2011;41:821-842. doi: 10.1007/s00726-010-0528-0.
36. Altwegg LA, Neidhart M, Hersberger M, Müller S, Eberli FR, Corti R, Roffi M, Sütsch G, Gay S, von Eckardstein A, Wischnewsky MB, Lüscher TF, Maier W. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J. 2007;28:941-948. doi: 10.1093/eurheartj/ehm078.
37. Miyamoto S, Ueda M, Ikemoto M, Naruko T, Itoh A, Tamaki S, Nohara R, Terasaki F, Sasayama S, Fujita M. Increased serum levels and expression of S100A8/A9 complex in infiltrated neutrophils in atherosclerotic plaque of unstable angina. Heart. 2008;94:1002-1007. doi: 10.1136/hrt.2007.121640.
38. van Leeuwen M, Gijbels MJ, Duijvestijn A, Smook M, van de Gaar MJ, Heeringa P, de Winther MP, Tervaert JW. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arterioscler Thromb Vasc Biol. 2008;28:84-89. doi: 10.1161/ATVBAHA.107.154807.
39. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res. 2008;102:1239-1246. doi: 10.1161/CIRCRESAHA.107.167544.
40. Consolo M, Amoroso A, Spandidos DA, Mazzarino MC. Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease (Review). Int J Mol Med. 2009;24:143-152.
41. Schelbergen RF, Blom AB, van den Bosch MH, Slöetjes A, Abdollahi-Roodsaz S, Schreurs BW, Mort JS, Vogl T, Roth J, van den Berg WB, van Lent PL. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum. 2012;64:1477-1487. doi: 10.1002/art.33495.
42. Passey RJ, Williams E, Lichanska AM, Wells C, Hu S, Geczy CL, Little MH, Hume DA. A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol. 1999;163:2209-2216.
43. Kuipers MT, Vogl T, Aslami H, Jongsma G, van den Berg E, Vlaar AP, Roelofs JJ, Juffermans NP, Schultz MJ, van der Poll T, Roth J, Wieland CW. High levels of S100A8/A9 proteins aggravate ventilator-induced lung injury via TLR4 signaling. PLoS One. 2013;8:e68694. doi: 10.1371/journal.pone.0068694.
44. Hiroshima Y, Hsu K, Tedla N, Chung YM, Chow S, Herbert C, Geczy CL. S100A8 induces IL-10 and protects against acute lung injury. J Immunol. 2014;192:2800-2811. doi: 10.4049/jimmunol.1302556.
45. Ahn GO, Seita J, Hong BJ, Kim YE, Bok S, Lee CJ, Kim KS, Lee JC, Leeper NJ, Cooke JP, Kim HJ, Kim IH, Weissman IL, Brown JM. Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci U S A. 2014;111:2698-2703. doi: 10.1073/pnas.1320243111.
46. Dessing MC, Tammaro A, Pulskens WP, Teske GJ, Butter LM, Claessen N, van Eijk M, van der Poll T, Vogl T, Roth J, Florquin S, Leemans JC. The calcium-binding protein complex S100A8/A9 has a crucial role in controlling macrophage-mediated renal repair following ischemia/reperfusion. Kidney Int. 2015;87:85-94. doi: 10.1038/ki.2014.216.
47. Khammanivong A, Wang C, Sorenson BS, Ross KF, Herzberg MC. S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma. PLoS One. 2013;8:e69395. doi: 10.1371/journal.pone.0069395.
48. Vega RB, Rothermel BA, Weinheimer CJ, Kovacs A, Naseem RH, Bassel-Duby R, Williams RS, Olson EN. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc Natl Acad Sci U S A. 2003;100:669-674. doi: 10.1073/pnas.0237225100.
49. Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, Lorenz JN, Molkentin JD. Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice. Proc Natl Acad Sci U S A. 2002;99:4586-4591. doi: 10.1073/pnas.072647999.
50. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech. 2003;60:540-551. doi: 10.1002/jemt.10296.
51. Bhattacharya S, Bunick CG, Chazin WJ. Target selectivity in EF-hand calcium binding proteins. Biochim Biophys Acta. 2004;1742:69-79. doi: 10.1016/j.bbamcr.2004.09.002.
52. Caravita S, Wu SC, Secchi MB, Dadone V, Bencini C, Pierini S. Longterm effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease. Eur J Intern Med. 2011;22:518-521. doi: 10.1016/j.ejim.2011.02.005.
53. Naelten G, Liu KL, Lo M. Durable improvement of renal function after perindopril withdrawal in Lyon hypertensive rats. J Cardiovasc Pharmacol. 2011;57:240-245. doi: 10.1097/FJC.0b013e318204bb7b.
54. Rakusan D, Kujal P, Kramer HJ, Husková Z, Vanourková Z, VernerováZ, Mrázová I, Thumová M, Cervenka L, Vanecková I. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol. 2010;299:F758-F766. doi: 10.1152/ajprenal.00259.2010.
55. Guerrero EI, Ardanaz N, Sevilla MA, Arévalo MA, Montero MJ. Cardiovascular effects of nebivolol in spontaneously hypertensive rats persist after treatment withdrawal. J Hypertens. 2006;24:151-158.
56. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580-1589. doi: 10.1161/01.CIR.0000120390.68287.BB.